Abstract:BackgroundThe accurate measurement of serum steroid hormone levels is important in many endocrinologic diseases, including but not limited to congenital adrenal hyperplasia (CAH). Screening for CAH with 17-OH-progesterone immunoassays is known to yield many false-positive results. Furthermore, the differentiation between classical CAH and other non-classical CAH subtypes requires complex steroid profiling. We developed and evaluated the analytical performance of a simultaneous multiplex LC-MS/MS assay for 20 steroid hormones, and also established preliminary pediatric reference intervals for the evaluated steroid hormones.MethodsBriefly, sample preparation consists of serum sample mixing with internal standard and acetonitrile, followed by lipid extraction with methyl-tert-butyl ether. Derivatization is conducted using hydroxylamine. The LC-MS/MS system consists of an ACQUITY UPLC I-Class System (Waters Corporation, Milford, MA, USA) equipped with a Waters ACQUITY UPLC BEH C18 column (1.0×50 mm, 1.7 μm; Waters Corporation), and Xevo TQ-XS (Waters Corporation) MS/MS system. The linearity, within- and between-run precision, carryover, lower limits of detection (LOQ) and quantification (LOQ), and matrix effect/recovery were evaluated for aldosterone, cortisol, cortisone, 21-deoxycortisol, corticosterone, 11β-OH-testosterone, 11-ketotestosterone, 11-ketoandrostendione, 11β-OH-androstenedione, estrone, 11-deoxycortisol, 17-OH-pregnenolone, 11β-OH-progesterone, Dehydroepiandrosterone (DHEA), androstenedione, 11-deoxycorticosterone, testosterone, 17-OH-progesterone, 5α-dihydrotestosterone, pregnenolone, and progesterone. Depending on the analyte, approximately 40 residual pediatric samples (age 0.9900 for 19/20 hormones, and 0.9853 for corticosterone. Within-run precision (%CV) ranged from 2.24-13.04%, 3.30-12.27%, and 2.63-9.67% for low, medium, and high steroid hormone levels. Between-run precision (%CV) ranged from 3.91-23.86%, 2.97-27.35%, and 3.95-23.67% for low, medium, and high steroid hormone levels. Carryover (%) was <5% for 18/20 hormones, 6.61% for pregnenolone, and 8.24% for progesterone. LOD ranged from 0.005-0.25 ng/mL, and LOQ ranged from 0.01-0.5 ng/mL for all 20 hormones. Matrix effect ranged from 99.0-110.6% for all 20 hormones, and recovery was 69.4-88.1% for 19/20 hormones, and 59.7% for aldosterone. Preliminary reference intervals (2.5-97.5 percentile) were successfully established for 18/20 evaluated hormones (ng/mL): aldosterone (0.010-0.186), cortisol (23.4-80.8), cortisone (5.82-24.8), 21-deoxycortisol (0.130-0.226), corticosterone (0.088-1.501), 11β-OH-testosterone (0.001-0.021), 11-ketotestosterone (0.031-0.390), 11-ketoandrostendione (0.031-0.390), 11β-OH-androstenedione (0.024-0.279), 11-deoxycortisol (0.040-0.701), 17-OH-pregnenolone (0.112-1.994), 11β-OH-progesterone (0.001-0.316), DHEA (0.018-1.452), androstenedione (0.010-0.160), 11-deoxycorticosterone (0.016-0.175), testosterone (0.015-0.096), 17-OH-progesterone (0.020-0.251), pregnenolone (0.031-0.215), and progesterone (0.010-0.048).ConclusionsThe LC-MS/MS-based multiplex steroid hormone assay showed robust analytical performance for all evaluated parameters, and can be used to reliably measure 20 steroid hormones with good sensitivity and specificity. This assay can be utilized in the clinical laboratory for the accurate diagnosis of various endocrinologic diseases, including rare subtypes of CAH, which can ultimately lead to better clinical outcomes.

Serum Steroid Profiling in the Diagnosis of Adrenocortical Carcinoma: A Prospective Cohort Study

Influence of sex and functional status on the value of serum steroid profiling in discriminating adrenocortical carcinoma from adrenocortical adenoma

Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma

ODP034 Circulating Protein Biomarkers for Discriminating Malignant from Benign Adrenal Tumors Using Mass Spectrometry-Based Proteomic Analysis

Comparison the characteristics of serum adrenocortical hormone profile in patients with adrenal cortical carcinoma and adrenal coritcal adenoma

Steroid profiling in adrenal disease

Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism

Molecular Cluster Mining of Adrenocortical Carcinoma Via Multi-Omics Data Analysis Aids Precise Clinical Therapy.

B-163 Development of a Multiplex Serum Steroid Profiling Assay Utilizing Liquid Chromatography-Mass Spectrometry

An LC–MS/MS method for steroid profiling during adrenal venous sampling for investigation of primary aldosteronism

Multiplexed steroid profiling of gluco- and mineralocorticoids pathways using a liquid chromatography tandem mass spectrometry method

OR02-04 Peripheral Blood Steroid Profiling Discriminates Aldosterone-producing Adenoma Genotypes From Bilateral Primary Aldosteronism

SAT-166 Advantage and Trustworthy of Cortisol and Dexamethasone Evaluation in Different Biological Matrices in Patients with Adrenal Masses

Steroid biomarkers for identifying non-classic adrenal hyperplasia due to 21-hydroxylase deficiency in a population of PCOS with suspicious levels of 17OH-progesterone

Mass spectrometry-based cortisol profiling during adrenal venous sampling reveals misdiagnosis for subtyping primary aldosteronism

The Role of Immunohistochemical Markers for the Diagnosis and Prognosis of Adrenocortical Neoplasms

Gas Chromatography–Mass Spectrometry Analysis of Urinary Steroid Metabolomics for Detection of Early Signs of Adrenal Neoplasm Malignancy in Patients with Cushing’s Syndrome

Urine steroid metabolomics as a diagnostic tool in primary aldosteronism

Determination of three C18‐oxygenated steroids in adrenal lesion segments in primary aldosteronism by super‐selective adrenal venous sampling and LC/ESI–MS/MS

Differentiation between adrenocortical carcinoma and lipid-poor adrenal adenoma using a multiparametric MRI-based diagnostic algorithm

Preoperative Prognostic Nomogram for Prophylactic Steroid Treatment of Patients with Subclinical Cushing’s Syndrome